Comparator supply for NCT06172296
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Sponsor: National Cancer Institute (NCI) (NIH). Phase: PHASE3. Status: Recruiting. Countries: United States, Australia, Canada, New Zealand, Puerto Rico. Last update posted 2026-09-08.
Registry record: https://clinicaltrials.gov/study/NCT06172296.
Canadian-labelled carboplatin
3 marketed Canadian product(s) from 3 manufacturer(s) contain carboplatin. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled carboplatin hexal
3 marketed Canadian product(s) from 3 manufacturer(s) contain carboplatin. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cisplatin
4 marketed Canadian product(s) from 4 manufacturer(s) contain cisplatin. Available strengths: 1 MG, 1.0 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cyclophosphamide
10 marketed Canadian product(s) from 3 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cyclophosphamide monohydrate
10 marketed Canadian product(s) from 3 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled doxorubicin
7 marketed Canadian product(s) from 5 manufacturer(s) contain doxorubicin hydrochloride. Available strengths: 150 MG, 2 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled etoposide
3 marketed Canadian product(s) from 3 manufacturer(s) contain etoposide. Available strengths: 20 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled irinotecan
6 marketed Canadian product(s) from 4 manufacturer(s) contain irinotecan hydrochloride. Available strengths: 100 MG / 5 ML, 20 MG, 500 MG / 25 ML. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled isotretinoin
12 marketed Canadian product(s) from 4 manufacturer(s) contain isotretinoin. Available strengths: 10 MG, 16 MG, 20 MG, 24 MG, 30 MG, 32 MG, 40 MG, 8 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled melphalan
1 marketed Canadian product(s) from 1 manufacturer(s) contain melphalan. Available strengths: 2 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled melphalan for injection-hepatic delivery system
1 marketed Canadian product(s) from 1 manufacturer(s) contain melphalan. Available strengths: 2 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled temozolomide
25 marketed Canadian product(s) from 5 manufacturer(s) contain temozolomide. Available strengths: 100 MG, 140 MG, 20 MG, 250 MG, 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thiotepa
7 marketed Canadian product(s) from 3 manufacturer(s) contain thiotepa. Available strengths: 100 MG, 15 MG, 400 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled topotecan
4 marketed Canadian product(s) from 4 manufacturer(s) contain topotecan (topotecan hydrochloride). Available strengths: 1 MG, 4 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled vincristine
2 marketed Canadian product(s) from 2 manufacturer(s) contain vincristine sulfate. Available strengths: 1 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled carboplatin as a trial comparator?
Yes. We source Canadian-marketed carboplatin under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT06172296.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1-431-588-9055.